Top

Published in:

01-02-2013 | Review

Atrogin-1, MuRF-1, and sarcopenia

Authors: Jonathan P. Gumucio, Christopher L. Mendias

Published in: Endocrine | Issue 1/2013

Abstract

Sarcopenia is one of the leading causes of disability in the elderly. Despite the growing prevalence of sarcopenia, the molecular mechanisms that control aging-related changes in muscle mass are not fully understood. The ubiquitin proteasome system is one of the major pathways that regulate muscle protein degradation, and this system plays a central role in controlling muscle size. Atrogin-1 and MuRF-1 are two E3 ubiquitin ligases that are important regulators of ubiquitin-mediated protein degradation in skeletal muscle. In this review, we will discuss: (i) aging-related changes to skeletal muscle structure and function; (ii) the regulation of protein synthesis and protein degradation by IGF-1, TGF-β, and myostatin, with emphasis on the control of atrogin-1 and MuRF-1 expression; and (iii) the potential for modulating atrogin-1 and MuRF-1 expression to treat or prevent sarcopenia.

I.H. Rosenberg, Summary comments. Am. J. Clin. Nutr. 50(5), 1231–1233 (1989)

R.A. Fielding, B. Vellas, W.J. Evans, S. Bhasin, J.E. Morley, A.B. Newman, G. Abellan van Kan, S. Andrieu, J. Bauer, D. Breuille, T. Cederholm, J. Chandler, C. De Meynard, L. Donini, T. Harris, A. Kannt, F. Keime Guibert, G. Onder, D. Papanicolaou, Y. Rolland, D. Rooks, C. Sieber, E. Souhami, S. Verlaan, M. Zamboni, Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J. Am. Med. Dir. Assoc. 12(4), 249–256 (2011). doi:10.1016/j.jamda.2011.01.003 PubMedCrossRef

I. Janssen, The epidemiology of sarcopenia. Clin. Geriatr. Med. 27(3), 355–363 (2011). doi:10.1016/j.cger.2011.03.004 PubMedCrossRef

C.J. Evans, C.-F. Chiou, K.A. Fitzgerald, W.J. Evans, B.R. Ferrell, W. Dale, L.P. Fried, S.R. Gandra, B. Dennee-Sommers, D.L. Patrick, Development of a new patient-reported outcome measure in sarcopenia. J. Am. Med. Dir. Assoc. 12(3), 226–233 (2011). doi:10.1016/j.jamda.2010.09.010 PubMedCrossRef

I. Janssen, D.S. Shepard, P.T. Katzmarzyk, R. Roubenoff, The healthcare costs of sarcopenia in the United States. J. Am. Geriatr. Soc. 52(1), 80–85 (2004)PubMedCrossRef

J.E. Morley, Sarcopenia: diagnosis and treatment. J. Nutr. Health Aging 12(7), 452–456 (2008)PubMedCrossRef

J.A. Faulkner, C.S. Davis, C.L. Mendias, S.V. Brooks, The aging of elite male athletes: age-related changes in performance and skeletal muscle structure and function. Clin. J. Sport Med. 18(6), 501–507 (2008). doi:10.1097/JSM.0b013e3181845f1c PubMedCrossRef

I. Janssen, S.B. Heymsfield, Z.M. Wang, R. Ross, Skeletal muscle mass and distribution in 468 men and women aged 18–88 yr. J. Appl. Physiol. 89(1), 81–88 (2000)PubMed

J. Lexell, Human aging, muscle mass, and fiber type composition. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 50, 11–16 (1995)

10.

G.A. Power, B.H. Dalton, D.G. Behm, A.A. Vandervoort, T.J. Doherty, C.L. Rice, Motor unit number estimates in masters runners: use it or lose it? Med. Sci. Sports Exerc. 42(9), 1644–1650 (2010). doi:10.1249/MSS.0b013e3181d6f9e9 PubMedCrossRef

11.

S. Trappe, P. Gallagher, M. Harber, J. Carrithers, J. Fluckey, T. Trappe, Single muscle fibre contractile properties in young and old men and women. J. Physiol. 552(Pt 1), 47–58 (2003). doi:10.1113/jphysiol.2003.044966 PubMedCrossRef

12.

D.R. Claflin, L.M. Larkin, P.S. Cederna, J.F. Horowitz, N.B. Alexander, N.M. Cole, A.T. Galecki, S. Chen, L.V. Nyquist, B.M. Carlson, J.A. Faulkner, J.A. Ashton-Miller, Effects of high- and low-velocity resistance training on the contractile properties of skeletal muscle fibers from young and older humans. J. Appl. Physiol. 111(4), 1021–1030 (2011). doi:10.1152/japplphysiol.01119.2010 PubMedCrossRef

13.

J. Lexell, C.C. Taylor, M. Sjostrom, What is the cause of the ageing atrophy? Total number, size and proportion of different fiber types studied in whole vastus lateralis muscle from 15- to 83-year-old men. J. Neurol. Sci. 84(2–3), 275–294 (1988)PubMedCrossRef

14.

F. Favier, H. Benoit, D. Freyssenet, Cellular and molecular events controlling skeletal muscle mass in response to altered use. Pflügers Archiv. 456(3), 587–600 (2008). doi:10.1007/s00424-007-0423-z PubMedCrossRef

15.

T.J. Hawke, D.J. Garry, Myogenic satellite cells: physiology to molecular biology. J. Appl. Physiol. 91(2), 534–551 (2001)PubMed

16.

I.M. Conboy, T.A. Rando, Aging, stem cells and tissue regeneration: lessons from muscle. Cell Cycle 4(3), 407–410 (2005)PubMedCrossRef

17.

F. Kadi, N. Charifi, C. Denis, J. Lexell, Satellite cells and myonuclei in young and elderly women and men. Muscle Nerve 29(1), 120–127 (2004). doi:10.1002/mus.10510 PubMedCrossRef

18.

B.M. Carlson, J.A. Faulkner, Muscle transplantation between young and old rats: age of host determines recovery. Am. J. Physiol. 256(6 Pt 1), C1262–C1266 (1989)PubMed

19.

I.M. Conboy, M.J. Conboy, A.J. Wagers, E.R. Girma, I.L. Weissman, T.A. Rando, Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature 433(7027), 760–764 (2005). doi:10.1038/nature03260 PubMedCrossRef

20.

V. Mouly, A. Aamiri, A. Bigot, R.N. Cooper, S. Di Donna, D. Furling, T. Gidaro, V. Jacquemin, K. Mamchaoui, E. Negroni, S. Périé, V. Renault, S.D. Silva-Barbosa, G.S. Butler-Browne, The mitotic clock in skeletal muscle regeneration, disease and cell mediated gene therapy. Acta Physiol. Scand. 184(1), 3–15 (2005). doi:10.1111/j.1365-201X.2005.01417.x PubMedCrossRef

21.

R.M. Reznick, H. Zong, J. Li, K. Morino, I.K. Moore, H.J. Yu, Z.X. Liu, J. Dong, K.J. Mustard, S.A. Hawley, D. Befroy, M. Pypaert, D.G. Hardie, L.H. Young, G.I. Shulman, Aging-associated reductions in AMP-activated protein kinase activity and mitochondrial biogenesis. Cell Metab. 5(2), 151–156 (2007). doi:10.1016/j.cmet.2007.01.008 PubMedCrossRef

22.

U.T. Brunk, A. Terman, The mitochondrial-lysosomal axis theory of aging: accumulation of damaged mitochondria as a result of imperfect autophagocytosis. Eur. J. Biochem. 269(8), 1996–2002 (2002)PubMedCrossRef

23.

E. Marzetti, J.M. Lawler, A. Hiona, T. Manini, A.Y. Seo, C. Leeuwenburgh, Modulation of age-induced apoptotic signaling and cellular remodeling by exercise and calorie restriction in skeletal muscle. Free Radic. Biol. Med. 44(2), 160–168 (2008). doi:10.1016/j.freeradbiomed.2007.05.028 PubMedCrossRef

24.

E. Marzetti, J.C.Y. Hwang, H.A. Lees, S.E. Wohlgemuth, E.E. Dupont-Versteegden, C.S. Carter, R. Bernabei, C. Leeuwenburgh, Mitochondrial death effectors: relevance to sarcopenia and disuse muscle atrophy. Biochim. Biophys. Acta 1800(3), 235–244 (2010). doi:10.1016/j.bbagen.2009.05.007 PubMedCrossRef

25.

A. Musaro, K. McCullagh, A. Paul, L. Houghton, G. Dobrowolny, M. Molinaro, E.R. Barton, H.L. Sweeney, N. Rosenthal, Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 27(2), 195–200 (2001). doi:10.1038/84839 PubMedCrossRef

26.

M.D. Mavalli, D.J. DiGirolamo, Y. Fan, R.C. Riddle, K.S. Campbell, T. van Groen, S.J. Frank, M.A. Sperling, K.A. Esser, M.M. Bamman, T.L. Clemens, Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. J. Clin. Investig. 120(11), 4007–4020 (2010). doi:10.1172/JCI42447 PubMedCrossRef

27.

Mozzetti Marone, D. Ritis, Scambia Pierelli, Semiquantitative RT-PCR analysis to assess the expression levels of multiple transcripts from the same sample. Biol Proced Online 3, 19–25 (2001). doi:10.1251/bpo20 PubMedCrossRef

28.

S. Schiaffino, C. Mammucari, Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models. Skelet. Muscle 1(1), 4 (2011). doi:10.1186/2044-5040-1-4 PubMedCrossRef

29.

M. Miyazaki, J.J. McCarthy, K.A. Esser, Insulin like growth factor-1-induced phosphorylation and altered distribution of tuberous sclerosis complex (TSC)1/TSC2 in C2C12 myotubes. FEBS J. 277(9), 2180–2191 (2010). doi:10.1111/j.1742-4658.2010.07635.x PubMedCrossRef

30.

M. Andjelkovic, D.R. Alessi, R. Meier, A. Fernandez, N.J. Lamb, M. Frech, P. Cron, P. Cohen, J.M. Lucocq, B.A. Hemmings, Role of translocation in the activation and function of protein kinase B. J. Biol. Chem. 272(50), 31515–31524 (1997)PubMedCrossRef

31.

I. Vivanco, C.L. Sawyers, The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2(7), 489–501 (2002). doi:10.1038/nrc839 PubMedCrossRef

32.

G. Goldspink, Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology 20, 232–238 (2005). doi:10.1152/physiol.00004.2005 PubMedCrossRef

33.

R.W. Matheny, B.C. Nindl, M.L. Adamo, Minireview: mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology 151(3), 865–875 (2010). doi:10.1210/en.2009-1217 PubMedCrossRef

34.

M. Vinciguerra, A. Musarò, N. Rosenthal, Regulation of muscle atrophy in aging and disease. Adv. Exp. Med. Biol. 694, 211–233 (2010)PubMedCrossRef

35.

S.C. Bodine, E. Latres, S. Baumhueter, V.K. Lai, L. Nunez, B.A. Clarke, W.T. Poueymirou, F.J. Panaro, E. Na, K. Dharmarajan, Z.Q. Pan, D.M. Valenzuela, T.M. DeChiara, T.N. Stitt, G.D. Yancopoulos, D.J. Glass, Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294(5547), 1704–1708 (2001). doi:10.1126/science.1065874 PubMedCrossRef

36.

C. Rommel, S.C. Bodine, B.A. Clarke, R. Rossman, L. Nunez, T.N. Stitt, G.D. Yancopoulos, D.J. Glass, Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat. Cell Biol. 3(11), 1009–1013 (2001). doi:10.1038/ncb1101-1009 PubMedCrossRef

37.

M. Sandri, Signaling in muscle atrophy and hypertrophy. Physiology 23, 160–170 (2008). doi:10.1152/physiol.00041.2007 PubMedCrossRef

38.

Y.-H. Song, M. Godard, Y. Li, S.R. Richmond, N. Rosenthal, P. Delafontaine, Insulin-like growth factor I-mediated skeletal muscle hypertrophy is characterized by increased mTOR-p70S6K signaling without increased Akt phosphorylation. J. Investig. Med. 53(3), 135–142 (2005)PubMedCrossRef

39.

R.A. Frost, C.H. Lang, mTor signaling in skeletal muscle during sepsis and inflammation: where does it all go wrong? Physiology 26(2), 83–96 (2011). doi:10.1152/physiol.00044.2010 PubMedCrossRef

40.

K. Inoki, Y. Li, T. Zhu, J. Wu, K.L. Guan, TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4(9), 648–657 (2002). doi:10.1038/ncb839 PubMedCrossRef

41.

B. Raught, F. Peiretti, A.C. Gingras, M. Livingstone, D. Shahbazian, G.L. Mayeur, R.D. Polakiewicz, N. Sonenberg, J.W. Hershey, Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J. 23(8), 1761–1769 (2004). doi:10.1038/sj.emboj.7600193 PubMedCrossRef

42.

R. Zoncu, A. Efeyan, D.M. Sabatini, mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12(1), 21–35 (2011). doi:10.1038/nrm3025 PubMedCrossRef

43.

K. Hara, K. Yonezawa, M.T. Kozlowski, T. Sugimoto, K. Andrabi, Q.P. Weng, M. Kasuga, I. Nishimoto, J. Avruch, Regulation of eIF-4E BP1 phosphorylation by mTOR. J. Biol. Chem. 272(42), 26457–26463 (1997)PubMedCrossRef

44.

Y. Izumiya, T. Hopkins, C. Morris, K. Sato, L. Zeng, J. Viereck, J.A. Hamilton, N. Ouchi, N.K. LeBrasseur, K. Walsh, Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab. 7(2), 159–172 (2008). doi:10.1016/j.cmet.2007.11.003 PubMedCrossRef

45.

G. Pallafacchina, E. Calabria, A.L. Serrano, J.M. Kalhovde, S. Schiaffino, A protein kinase B-dependent and rapamycin-sensitive pathway controls skeletal muscle growth but not fiber type specification. Proc. Natl. Acad. Sci. USA 99(14), 9213–9218 (2002). doi:10.1073/pnas.142166599 PubMedCrossRef

46.

M. Miyazaki, K.A. Esser, Cellular mechanisms regulating protein synthesis and skeletal muscle hypertrophy in animals. J. Appl. Physiol. 106(4), 1367–1373 (2009). doi:10.1152/japplphysiol.91355.2008 PubMedCrossRef

47.

E. Marzetti, G. Privitera, V. Simili, S.E. Wohlgemuth, L. Aulisa, M. Pahor, C. Leeuwenburgh, Multiple pathways to the same end: mechanisms of myonuclear apoptosis in sarcopenia of aging. Scientific World J. 10, 340–349 (2010). doi:10.1100/tsw.2010.27 CrossRef

48.

T.W. Buford, S.D. Anton, A.R. Judge, E. Marzetti, S.E. Wohlgemuth, C.S. Carter, C. Leeuwenburgh, M. Pahor, T.M. Manini, Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy. Ageing Res. Rev. 9(4), 369–383 (2010). doi:10.1016/j.arr.2010.04.004 PubMedCrossRef

49.

A.C. McPherron, A.M. Lawler, S.J. Lee, Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387(6628), 83–90 (1997). doi:10.1038/387083a0 PubMedCrossRef

50.

C.L. Mendias, J.E. Marcin, D.R. Calerdon, J.A. Faulkner, Contractile properties of EDL and soleus muscles of myostatin-deficient mice. J. Appl. Physiol. 101(3), 898–905 (2006). doi:10.1152/japplphysiol.00126.2006 PubMedCrossRef

51.

B.A. Gentry, J.A. Ferreira, C.L. Phillips, M. Brown, Hindlimb skeletal muscle function in myostatin-deficient mice. Muscle Nerve 43(1), 49–57 (2011). doi:10.1002/mus.21796 PubMedCrossRef

52.

T.A. Zimmers, M.V. Davies, L.G. Koniaris, P. Haynes, A.F. Esquela, K.N. Tomkinson, A.C. McPherron, N.M. Wolfman, S.-J. Lee, Induction of cachexia in mice by systemically administered myostatin. Science 296(5572), 1486–1488 (2002). doi:10.1126/science.1069525 PubMedCrossRef

53.

C.L. Mendias, J.P. Gumucio, M.E. Davis, C.W. Bromley, C.S. Davis, S.V. Brooks, Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve 45(1), 55–59 (2012). doi:10.1002/mus.22232 PubMedCrossRef

54.

S.J. Lee, Y.S. Lee, T.A. Zimmers, A. Soleimani, M.M. Matzuk, K. Tsuchida, R.D. Cohn, E.R. Barton, Regulation of muscle mass by follistatin and activins. Mol. Endocrinol. 24(10), 1998–2008 (2010). doi:10.1210/me.2010-0127 PubMedCrossRef

55.

S.J. Lee, A.C. McPherron, Regulation of myostatin activity and muscle growth. Proc. Natl. Acad. Sci. USA 98(16), 9306–9311 (2001). doi:10.1073/pnas.151270098 PubMedCrossRef

56.

B. Philip, Z. Lu, Y. Gao, Regulation of GDF-8 signaling by the p38 MAPK. Cell. Signal. 17(3), 365–375 (2005). doi:10.1016/j.cellsig.2004.08.003 PubMedCrossRef

57.

R. Sartori, G. Milan, M. Patron, C. Mammucari, B. Blaauw, R. Abraham, M. Sandri, Smad2 and 3 transcription factors control muscle mass in adulthood. Am. J. Physiol. Cell Physiol. 296(6), C1248–C1257 (2009). doi:10.1152/ajpcell.00104.2009 PubMedCrossRef

58.

Y. Shi, J. Massagué, Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113(6), 685–700 (2003)PubMedCrossRef

59.

L. Yu, M.C. Hébert, Y.E. Zhang, TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. EMBO J. 21(14), 3749–3759 (2002). doi:10.1093/emboj/cdf366 PubMedCrossRef

60.

X. Zhu, S. Topouzis, L.-F. Liang, R.L. Stotish, Myostatin signaling through Smad2, Smad3 and Smad4 is regulated by the inhibitory Smad7 by a negative feedback mechanism. Cytokine 26(6), 262–272 (2004). doi:10.1016/j.cyto.2004.03.007 PubMedCrossRef

61.

H.D. Kollias, J.C. McDermott, Transforming growth factor-beta and myostatin signaling in skeletal muscle. J. Appl. Physiol. 104(3), 579–587 (2008). doi:10.1152/japplphysiol.01091.2007 PubMedCrossRef

62.

R.R. Gomis, C. Alarcón, W. He, Q. Wang, J. Seoane, A. Lash, J. Massagué, A FoxO-Smad synexpression group in human keratinocytes. Proc. Natl. Acad. Sci. USA 103(34), 12747–12752 (2006). doi:10.1073/pnas.0605333103 PubMedCrossRef

63.

J. Seoane, H.-V. Le, L. Shen, S.A. Anderson, J. Massagué, Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117(2), 211–223 (2004)PubMedCrossRef

64.

T. Zarubin, J. Han, Activation and signaling of the p38 MAP kinase pathway. Cell Res. 15(1), 11–18 (2005). doi:10.1038/sj.cr.7290257 PubMedCrossRef

65.

A. Amirouche, A.-C. Durieux, S. Banzet, N. Koulmann, R. Bonnefoy, C. Mouret, X. Bigard, A. Peinnequin, D. Freyssenet, Down-regulation of Akt/mammalian target of rapamycin signaling pathway in response to myostatin overexpression in skeletal muscle. Endocrinology 150(1), 286–294 (2009). doi:10.1210/en.2008-0959 PubMedCrossRef

66.

C. McFarlane, E. Plummer, M. Thomas, A. Hennebry, M. Ashby, N. Ling, H. Smith, M. Sharma, R. Kambadur, Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism. J. Cell. Physiol. 209(2), 501–514 (2006). doi:10.1002/jcp.20757 PubMedCrossRef

67.

A.U. Trendelenburg, A. Meyer, D. Rohner, J. Boyle, S. Hatakeyama, D.J. Glass, Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am. J. Physiol. Cell Physiol. 296(6), C1258–C1270 (2009). doi:10.1152/ajpcell.00105.2009 PubMedCrossRef

68.

W. Yang, Y. Zhang, Y. Li, Z. Wu, D. Zhu, Myostatin induces cyclin D1 degradation to cause cell cycle arrest through a phosphatidylinositol 3-kinase/AKT/GSK-3 beta pathway and is antagonized by insulin-like growth factor 1. J. Biol. Chem. 282(6), 3799–3808 (2007). doi:10.1074/jbc.M610185200 PubMedCrossRef

69.

M.D. Gomes, S.H. Lecker, R.T. Jagoe, A. Navon, A.L. Goldberg, Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc. Natl. Acad. Sci. USA 98(25), 14440–14445 (2001). doi:10.1073/pnas.251541198 PubMedCrossRef

70.

S. Lokireddy, C. McFarlane, X. Ge, H. Zhang, S.K. Sze, M. Sharma, R. Kambadur, Myostatin induces degradation of sarcomeric proteins through a Smad3 signaling mechanism during skeletal muscle wasting. Mol. Endocrinol. 25(11), 1936–1949 (2011). doi:10.1210/me.2011-1124 PubMedCrossRef

71.

C.L. Mendias, J.P. Gumucio, E.B. Lynch, Mechanical loading and TGF-beta change the expression of multiple miRNAs in tendon fibroblasts. J. Appl. Physiol. (2012). doi:10.1152/japplphysiol.00301.2012 PubMed

72.

C.L. Mendias, E. Kayupov, J.R. Bradley, S.V. Brooks, D.R. Claflin, Decreased specific force and power production of muscle fibers from myostatin-deficient mice are associated with a suppression of protein degradation. J. Appl. Physiol. 111(1), 185–191 (2011). doi:10.1152/japplphysiol.00126.2011 PubMedCrossRef

73.

J.M. Sacheck, J.-P.K. Hyatt, A. Raffaello, R.T. Jagoe, R.R. Roy, V.R. Edgerton, S.H. Lecker, A.L. Goldberg, Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J. 21(1), 140–155 (2007). doi:10.1096/fj.06-6604com PubMedCrossRef

74.

Y.-P. Li, Y. Chen, J. John, J. Moylan, B. Jin, D.L. Mann, M.B. Reid, TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. 19(3), 362–370 (2005). doi:10.1096/fj.04-2364com PubMedCrossRef

75.

J.M. McClung, A.R. Judge, S.K. Powers, Z. Yan, p38 MAPK links oxidative stress to autophagy-related gene expression in cachectic muscle wasting. Am. J. Physiol. Cell Physiol. 298(3), C542–C549 (2010). doi:10.1152/ajpcell.00192.2009 PubMedCrossRef

76.

T.J. McLoughlin, S.M. Smith, A.D. DeLong, H. Wang, T.G. Unterman, K.A. Esser, FoxO1 induces apoptosis in skeletal myotubes in a DNA-binding-dependent manner. Am. J. Physiol. Cell Physiol. 297(3), C548–C555 (2009). doi:10.1152/ajpcell.00502.2008 PubMedCrossRef

77.

S.M. Senf, S.L. Dodd, A.R. Judge, FOXO signaling is required for disuse muscle atrophy and is directly regulated by Hsp70. Am. J. Physiol. Cell Physiol. 298(1), C38–C45 (2010). doi:10.1152/ajpcell.00315.2009 PubMedCrossRef

78.

T.N. Stitt, D. Drujan, B.A. Clarke, F. Panaro, Y. Timofeyva, W.O. Kline, M. Gonzalez, G.D. Yancopoulos, D.J. Glass, The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell 14(3), 395–403 (2004)PubMedCrossRef

79.

A.R. Conery, Y. Cao, E.A. Thompson, C.M. Townsend, T.C. Ko, K. Luo, Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat. Cell Biol. 6(4), 366–372 (2004)PubMedCrossRef

80.

F. Haddad, G.R. Adams, Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy. J. Appl. Physiol. 100(4), 1188–1203 (2006). doi:10.1152/japplphysiol.01227.2005 PubMedCrossRef

81.

S. Clavel, A.-S. Coldefy, E. Kurkdjian, J. Salles, I. Margaritis, B. Derijard, Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat Tibialis Anterior muscle. Mech. Ageing Dev. 127(10), 794–801 (2006). doi:10.1016/j.mad.2006.07.005 PubMedCrossRef

82.

E. Edström, M. Altun, M. Hägglund, B. Ulfhake, Atrogin-1/MAFbx and MuRF1 are downregulated in aging-related loss of skeletal muscle. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 61(7), 663–674 (2006)CrossRef

83.

J.A. Rahnert, Q. Luo, E.M. Balog, A.J. Sokoloff, T.J. Burkholder, Changes in growth-related kinases in head, neck and limb muscles with age. Exp. Gerontol. 46(4), 282–291 (2011). doi:10.1016/j.exger.2010.11.004 PubMedCrossRef

84.

M. Gaugler, A. Brown, E. Merrell, M. DiSanto-Rose, J.A. Rathmacher, T.H. Reynolds, PKB signaling and atrogene expression in skeletal muscle of aged mice. J. Appl. Physiol. 111(1), 192–199 (2011). doi:10.1152/japplphysiol.00175.2011 PubMedCrossRef

85.

S.R. Kimball, J.P. O'Malley, J.C. Anthony, S.J. Crozier, L.S. Jefferson, Assessment of biomarkers of protein anabolism in skeletal muscle during the life span of the rat: sarcopenia despite elevated protein synthesis. Am. J. Physiol. Endocrinol. Metab. 287(4), E772–E780 (2004). doi:10.1152/ajpendo.00535.2003 PubMedCrossRef

86.

A. Chalé-Rush, E.P. Morris, T.L. Kendall, N.E. Brooks, R.A. Fielding, Effects of chronic overload on muscle hypertrophy and mTOR signaling in young adult and aged rats. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 64(12), 1232–1239 (2009). doi:10.1093/gerona/glp146 CrossRef

87.

K.G. O’Connor, J.D. Tobin, S.M. Harman, C.C. Plato, T.A. Roy, S.S. Sherman, M.R. Blackman, Serum levels of insulin-like growth factor-I are related to age and not to body composition in healthy women and men. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 53(3), M176–M182 (1998)CrossRef

88.

M. Hameed, R.W. Orrell, M. Cobbold, G. Goldspink, S.D.R. Harridge, Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise. J. Physiol. 547(Pt 1), 247–254 (2003). doi:10.1113/jphysiol.2002.032136 PubMedCrossRef

89.

B. Léger, W. Derave, K. De Bock, P. Hespel, A.P. Russell, Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res. 11(1), 163B–175B (2008). doi:10.1089/rej.2007.0588 CrossRef

90.

C. Guillet, M. Prod’homme, M. Balage, P. Gachon, C. Giraudet, L. Morin, J. Grizard, Y. Boirie, Impaired anabolic response of muscle protein synthesis is associated with S6K1 dysregulation in elderly humans. FASEB J. 18(13), 1586–1587 (2004). doi:10.1096/fj.03-1341fje PubMed

91.

M.J. Drummond, H.C. Dreyer, B. Pennings, C.S. Fry, S. Dhanani, E.L. Dillon, M. Sheffield-Moore, E. Volpi, B.B. Rasmussen, Skeletal muscle protein anabolic response to resistance exercise and essential amino acids is delayed with aging. J. Appl. Physiol. 104(5), 1452–1461 (2008). doi:10.1152/japplphysiol.00021.2008 PubMedCrossRef

92.

M.E. Carlson, M.J. Conboy, M. Hsu, L. Barchas, J. Jeong, A. Agrawal, A.J. Mikels, S. Agrawal, D.V. Schaffer, I.M. Conboy, Relative roles of TGF-beta1 and Wnt in the systemic regulation and aging of satellite cell responses. Aging Cell 8(6), 676–689 (2009). doi:10.1111/j.1474-9726.2009.00517.x PubMedCrossRef

93.

M.E. Carlson, M. Hsu, I.M. Conboy, Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells. Nature 454(7203), 528–532 (2008). doi:10.1038/nature07034 PubMedCrossRef

94.

M. Altun, H.C. Besche, H.S. Overkleeft, R. Piccirillo, M.J. Edelmann, B.M. Kessler, A.L. Goldberg, B. Ulfhake, Muscle wasting in aged, sarcopenic rats is associated with enhanced activity of the ubiquitin proteasome pathway. J. Biol. Chem. 285(51), 39597–39608 (2010). doi:10.1074/jbc.M110.129718 PubMedCrossRef

95.

M. Bossola, F. Pacelli, P. Costelli, A. Tortorelli, F. Rosa, G.B. Doglietto, Proteasome activities in the rectus abdominis muscle of young and older individuals. Biogerontology 9(4), 261–268 (2008). doi:10.1007/s10522-008-9135-9 PubMedCrossRef

96.

D. Cai, K.K.H. Lee, M. Li, M.K. Tang, K.M. Chan, Ubiquitin expression is up-regulated in human and rat skeletal muscles during aging. Arch. Biochem. Biophys. 425(1), 42–50 (2004). doi:10.1016/j.abb.2004.02.027 PubMedCrossRef

97.

A. Ratkevicius, A. Joyson, I. Selmer, T. Dhanani, C. Grierson, A.M. Tommasi, A. Devries, P. Rauchhaus, D. Crowther, S. Alesci, P. Yaworsky, F. Gilbert, T.W. Redpath, J. Brady, K.C.H. Fearon, D.M. Reid, C.A. Greig, H. Wackerhage, Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. J. Gerontol. Ser. A Biol. Sci. Med. Sci. (2011). doi:10.1093/gerona/glr025

98.

U. Raue, D. Slivka, B. Jemiolo, C. Hollon, S. Trappe, Proteolytic gene expression differs at rest and after resistance exercise between young and old women. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 62(12), 1407–1412 (2007)CrossRef

99.

S.A. Whitman, M.J. Wacker, S.R. Richmond, M.P. Godard, Contributions of the ubiquitin-proteasome pathway and apoptosis to human skeletal muscle wasting with age. Pflügers Archiv. 450(6), 437–446 (2005). doi:10.1007/s00424-005-1473-8 PubMedCrossRef

100.

L. Di Luigi, F. Romanelli, P. Sgrò, A. Lenzi, Andrological aspects of physical exercise and sport medicine. Endocrine (2012). doi:10.1007/s12020-012-9655-6 PubMed

101.

S.C. Forbes, J.P. Little, D.G. Candow, Exercise and nutritional interventions for improving aging muscle health. Endocrine (2012). doi:10.1007/s12020-012-9676-1 PubMed

102.

C.K. Liu, R.A. Fielding, Exercise as an intervention for frailty. Clin. Geriatr. Med. 27(1), 101–110 (2011). doi:10.1016/j.cger.2010.08.001 PubMedCrossRef

103.

C.S. Fry, M.J. Drummond, E.L. Glynn, J.M. Dickinson, D.M. Gundermann, K.L. Timmerman, D.K. Walker, S. Dhanani, E. Volpi, B.B. Rasmussen, Aging impairs contraction-induced human skeletal muscle mTORC1 signaling and protein synthesis. Skelet. Muscle 1(1), 11 (2011). doi:10.1186/2044-5040-1-11 PubMedCrossRef

104.

U. Raue, D. Slivka, B. Jemiolo, C. Hollon, S. Trappe, Myogenic gene expression at rest and after a bout of resistance exercise in young (18–30 yr) and old (80–89 yr) women. J. Appl. Physiol. 101(1), 53–59 (2006). doi:10.1152/japplphysiol.01616.2005 PubMedCrossRef

105.

S. Trappe, M. Godard, P. Gallagher, C. Carroll, G. Rowden, D. Porter, Resistance training improves single muscle fiber contractile function in older women. Am. J. Physiol. Cell Physiol. 281(2), C398–C406 (2001)PubMed

106.

S. Trappe, D. Williamson, M. Godard, D. Porter, G. Rowden, D. Costill, Effect of resistance training on single muscle fiber contractile function in older men. J. Appl. Physiol. 89(1), 143–152 (2000)PubMed

107.

D.L. Williamson, U. Raue, D.R. Slivka, S. Trappe, Resistance exercise, skeletal muscle FOXO3A, and 85-year-old women. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 65(4), 335–343 (2010). doi:10.1093/gerona/glq005 CrossRef

108.

A.R. Konopka, M.D. Douglass, L.A. Kaminsky, B. Jemiolo, T.A. Trappe, S. Trappe, M.P. Harber, Molecular adaptations to aerobic exercise training in skeletal muscle of older women. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 65(11), 1201–1207 (2010). doi:10.1093/gerona/glq109 CrossRef

109.

A.R. Konopka, T.A. Trappe, B. Jemiolo, S.W. Trappe, M.P. Harber, Myosin heavy chain plasticity in aging skeletal muscle with aerobic exercise training. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 66(8), 835–841 (2011). doi:10.1093/gerona/glr088 CrossRef

110.

K.L. Bennell, R.S. Hinman, A review of the clinical evidence for exercise in osteoarthritis of the hip and knee. J. Sci. Med. Sport 14(1), 4–9 (2011). doi:10.1016/j.jsams.2010.08.002 PubMedCrossRef

111.

M.A. Williams, W.L. Haskell, P.A. Ades, E.A. Amsterdam, V. Bittner, B.A. Franklin, M. Gulanick, S.T. Laing, K.J. Stewart, Resistance exercise in individuals with and without cardiovascular disease: 2007 update: a scientific statement from the American Heart Association Council on Clinical Cardiology and Council on Nutrition, Physical Activity, and Metabolism. Circulation 116(5), 572–584 (2007). doi:10.1161/CIRCULATIONAHA.107.185214 PubMedCrossRef

112.

G.E. Butterfield, J. Thompson, M.J. Rennie, R. Marcus, R.L. Hintz, A.R. Hoffman, Effect of rhGH and rhIGF-I treatment on protein utilization in elderly women. Am. J. Physiol. 272(1 Pt 1), E94–E99 (1997)PubMed

113.

N. Lebrasseur, T. Schelhorn, B. Bernardo, P. Cosgrove, P. Loria, T. Brown, Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J. Gerontol. Ser. A Biol. Sci. Med. Sci. (2009). doi:10.1093/gerona/glp068

114.

K.T. Murphy, R. Koopman, T. Naim, B. Léger, J. Trieu, C. Ibebunjo, G.S. Lynch, Antibody-directed myostatin inhibition in 21-mo-old mice reveals novel roles for myostatin signaling in skeletal muscle structure and function. FASEB J. 24(11), 4433–4442 (2010). doi:10.1096/fj.10-159608 PubMedCrossRef

115.

R.D. Cohn, C. van Erp, J.P. Habashi, A.A. Soleimani, E.C. Klein, M.T. Lisi, M. Gamradt, C.M. ap Rhys, T.M. Holm, B.L. Loeys, F. Ramirez, D.P. Judge, C.W. Ward, H.C. Dietz, Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 13(2), 204–210 (2007). doi:10.1038/nm1536 PubMedCrossRef

116.

T.N. Burks, E. Andres-Mateos, R. Marx, R. Mejias, C. van Erp, J.L. Simmers, J.D. Walston, C.W. Ward, R.D. Cohn, Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. Sci. Transl. Med. 3(82), 82ra37 (2011). doi:10.1126/scitranslmed.3002227 PubMedCrossRef

Title: Atrogin-1, MuRF-1, and sarcopenia
Authors: Jonathan P. Gumucio
Christopher L. Mendias
Publication date: 01-02-2013
Publisher: Springer US
Published in: Endocrine / Issue 1/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-012-9751-7

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

1,5-Anhydroglucitol in diabetes mellitus

Hunting osteoporosis susceptibility genes: bigger is better but diverse is also welcome

Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches

A novel formulation of l-thyroxine (l-T4) reduces the problem of l-T4 malabsorption by coffee observed with traditional tablet formulations

The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis

Coronary microvascular function in patients with Cushing’s syndrome

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage